Kyntra Bio (KYNB) EBT Growth (3y) (2017 - 2026)
Kyntra Bio (KYNB) EBT Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 103.69% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 24.03% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 41.79% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 38.36% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -27.69% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 64.03% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.77% |
| Mar 31, 2026 | 41.97% |
| Dec 31, 2025 | 39.61% |
| Sep 30, 2025 | 47.71% |
| Jun 30, 2025 | 42.69% |
| Mar 31, 2025 | 35.82% |
| Dec 31, 2024 | 59.90% |
| Sep 30, 2024 | -43.81% |
| Jun 30, 2024 | 29.39% |
| Mar 31, 2024 | 11.76% |
| Dec 31, 2023 | -16.91% |
| Sep 30, 2023 | -57.84% |
| Jun 30, 2023 | -1.28% |
| Mar 31, 2023 | 0.48% |
| Dec 31, 2022 | 12.21% |
| Sep 30, 2022 | -23.04% |
| Jun 30, 2022 | -38.03% |
| Mar 31, 2022 | -11.75% |
| Dec 31, 2021 | -62.11% |
| Sep 30, 2021 | 46.87% |